Fox Chase Cancer Center News

RNA Next-Generation Sequencing Offers More Accurate, Less Invasive Analysis for Lung Cancers

PHILADELPHIA (November 18, 2022)—Genetically targeted therapy can make treatment for lung cancer much more effective, but testing to identify specific gene fusions involved in the disease remains a challenge. However, a new study by researchers at Fox Chase Cancer Center demonstrates that RNA next-generation sequencing (RNA-NGS) can offer results that are more accurate and comprehensive while using smaller tissue samples.

Fox Chase Cancer Center and Oryzon Genomics to Collaborate on Trial Investigating Safety and Efficacy of Iadademstat in Neuroendocrine and Small Cell Carcinomas

PHILADELPHIA (November 17, 2022)—Fox Chase Cancer Center and Oryzon Genomics S.A. will work together to test the safety and efficacy of the drug iadademstat in patients with pulmonary and extrapulmonary neuroendocrine carcinomas (NECs), which are rare and heterogeneous cancers arising from neuroendocrine cells, and small cell lung cancer (SCLC).


Fox Chase Study Reveals Mechanism for Repairing DNA Damage Caused by Environmental Triggers

PHILADELPHIA (November 17, 2022)—It’s long been known that DNA damage caused by environmental triggers, as well as other sources of oxidative stress, contribute to the development and progression of a wide variety of cancers. Now a new study by a Fox Chase Cancer Center scientist provides new insight into how an enzyme called apurinic/apyrimidinic 1 (APE1) repairs this damage.